எங்கள் குழு ஒவ்வொரு ஆண்டும் அமெரிக்கா, ஐரோப்பா மற்றும் ஆசியா முழுவதும் 1000 அறிவியல் சங்கங்களின் ஆதரவுடன் 3000+ உலகளாவிய மாநாட்டுத் தொடர் நிகழ்வுகளை ஏற்பாடு செய்து 700+ திறந்த அணுகல் இதழ்களை வெளியிடுகிறது, இதில் 50000 க்கும் மேற்பட்ட தலைசிறந்த ஆளுமைகள், புகழ்பெற்ற விஞ்ஞானிகள் ஆசிரியர் குழு உறுப்பினர்களாக உள்ளனர்.
அதிக வாசகர்கள் மற்றும் மேற்கோள்களைப் பெறும் திறந்த அணுகல் இதழ்கள்
700 இதழ்கள் மற்றும் 15,000,000 வாசகர்கள் ஒவ்வொரு பத்திரிகையும் 25,000+ வாசகர்களைப் பெறுகிறது
Takashi Yamazaki, Daiki Takano and Ken Nagata
Background and objective: Although hypertension, diabetes, dyslipidemia and congestive heart failure are now considered as vascular risk factors (VRFs) for Alzheimer’s disease (AD), it is still unclear whether they influence the effect of treatment in elderly AD patients. To elucidate the influence of VRFs on the effect of cholinesterase inhibitors, we investigated the relationship between the presence of VRF and evolution of cognitive function in AD patients. Methods: The present study included 174 patients (59 men and 115 women) who were diagnosed as having probable AD according to the NINCDS-ADRDA criteria. All patients underwent laboratory examination, neuropsychological evaluation including Mini-Mental State Examination (MMSE), and assessment of VRFs at baseline, and were treated with donepezil hydrochloride for 2 years. The evolution of the MMSE score was evaluated by comparing the total MMSE score between the baseline and 2 year follow-up. Results: The MMSE score was improved or unchanged from the baseline in 52 patients (responders), whereas the MMSE score declined from baseline in 122 patients (non-responders). The responder status correlated negatively with baseline MMSE scores (p<0.01) and positively with body mass index (P<0.05). Although the response to donepezil did not correlate statistically with the presence of VRFs in the overall analysis, there was a tendency that there were less responders when there were more VRFs. Conclusion: The present study suggested that a good nutritional state in addition to the aggressive treatment of VRFs may slow down the progression of cognitive deterioration in elderly AD patients on donepezil.